The overall procedural technical success rate, researchers reported, was 96.8%.

Rapid reperfusion is linked to improved survival for STEMI patients, but delayed care is still prevalent. 

Cardiac cath labs can achieve significant radiation dose reductions through focused, collaborative quality improvement (QI) efforts, according to a new analysis published in Circulation: Cardiovascular Interventions.

A new international research study will focus on treatment strategies and outcomes of ST-segment elevation myocardial infarction (STEMI) patients with known or suspected COVID-19.

The COVID-19 pandemic has changed the practice of cardiology as we know it, leading to supplies shortages, delayed procedures, and an at-risk patient population fearful of the road ahead. How has the outbreak affected cath labs?

Three-year data from the BIOFLOW-V trial, presented Feb. 23 at the 2020 CRT Congress in National Harbor, Md., reinforce the status of Biotronik’s Orsiro drug-eluting stent as superior to the popular Xience stent.

When the cardiac and neurovascular catheterization lab at Riverside University Health System Medical Center (RUHS-MC) treated its first patient last February, the opening represented many things to many people.

People with severe but stable ischemic heart disease don’t benefit any more from invasive CV procedures than they do from optimal medical therapy and lifestyle changes alone, according to results from the highly anticipated ISCHEMIA trial.